📰 Development Costs News
Page 55 - Development Costs News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Development Costs. Real-time updates on events, politics, business and more.
June 10, 2021
Der Gesundheitsminister sprach einem Bericht zufolge von einer der größeren Enttäuschungen beim Impfstoff des Tübinger Hersteller Curevac. Das Mittel galt lange als vielversprechend. Alle Infos im Newsblog.
June 10, 2021
Der Gesundheitsminister sprach einem Bericht zufolge von einer der größeren Enttäuschungen beim Impfstoff des Tübinger Hersteller Curevac. Das Mittel galt lange als vielversprechend. Alle Infos im Newsblog.
June 9, 2021
Der Gesundheitsminister sprach einem Bericht zufolge von einer der größeren Enttäuschungen beim Impfstoff des Tübinger Hersteller Curevac. Das Mittel galt lange als vielversprechend. Alle Infos im Newsblog.
June 1, 2021
CONVERSION OF PILOT PLANT INTO INFINITE LOOP DEMONSTRATION AND TRAINING FACILITY OBTAINED NO-OBJECTION LETTER FROM THE FDA ADVANCED STAGES OF PRE-FEASIBILITY ENGINEERING DESIGN FOR INFINITE LOOP COMMERCIAL
June 1, 2021
Der Gesundheitsminister sprach einem Bericht zufolge von einer der größeren Enttäuschungen beim Impfstoff des Tübinger Hersteller Curevac. Das Mittel galt lange als vielversprechend. Alle Infos im Newsblog.
May 31, 2021
Der Gesundheitsminister sprach einem Bericht zufolge von einer der größeren Enttäuschungen beim Impfstoff des Tübinger Hersteller Curevac. Das Mittel galt lange als vielversprechend. Alle Infos im Newsblog.
April 16, 2021
Altura Announces Fourth Quarter and Year End 2020 Results and Reserves April 16, 2021 EnergyNow Media CALGARY, AB, April 15, 2021 /CNW/ – Altura Energy Inc. (“Altura” or the “Company”) (TSXV: ATU) is pleased to announce its financial and operating results for the fourth quarter and year ended December 31, 2020 and the independent evaluation of the Company’s oil and natural gas reserves (the “McDaniel Report”), effective December 31, 2020, as pre...
April 7, 2021
Share this article Share this article ResearchAndMarkets.coms offering. This new report, Biomarkers: Technologies and Global Markets, provides a comprehensive analysis of the biomarkers market in a global context, including market forecasts and sales through 2025. The report analyzes the market, segmenting it into various product offerings (i.e., instruments, consumables [reagents, kits and panels], services and software). Segmentation also provides analysis by popular technology type (genomics...
March 17, 2021
“Adjusted funds flow”, “adjusted funds flow per share, basic and diluted”, “adjusted funds flow per boe”, “operating income” and “operating netback per boe” do not have a standardized meaning under International Financial Reporting Standards (IFRS) and GAAP and therefore may not be comparable with the calculations of similar measures for other companies. “Adjusted funds flow” adjusts for decommissioning expenditures from funds flow. Please refer to “Non-GAAP Financi...
March 8, 2021
(1) The above table includes non-GAAP financial measures which may not be comparable to other companies. Please see the "Non-GAAP Financial Measures" section of the accompanying Managements Discussion and Analysis. (2) Please refer to Supplemental Table 4 "Production" of the accompanying Managements Discussion and Analysis for disclosure by product type. Message to Shareholders Vermilion started 2020 on a strong footing in what appeared to be a constructive outlook for commodity prices. That a...